Modified Lenalidomide, Bortezomib, and Dexamethasone (RVD-lite) Regimen for Transplant-Ineligible Patients with Newly Diagnosed MM

Conference Correspondent  - TOP - ASH 2015 - Multiple Myeloma, Conference Correspondent

Multiple myeloma (MM) is primarily a disease of older adults, with a median age of 66 years at diagnosis. Based on results of the FIRST trial, the lenalidomide and dexamethasone (RD) regimen is considered the new standard of care in older, transplant-ineligible patients with newly diagnosed MM (NDMM).1 To further optimize treatment outcomes for this patient population, the present study evaluated the triple combination of bortezomib plus RD (RVD) but delivered on a modified dose and schedule (RVD-lite) in older patients with transplant-ineligible MM.2 The RVD-lite regimen consisted of a 35-day cycle of lenalidomide (15 mg, days 1-21) plus bortezomib (1.3 mg/m2 weekly subcutaneously on days 1, 8, 15, and 22), and dexamethasone (20 mg on days 1, 2, 8, 9, 15, 16, 22, and 23 for patients ≤75 years, and days 1, 8, 15, and 22 for those ≥75 years); bortezomib was administered intravenously in cycle 1 for the first 10 patients and subcutaneously thereafter.

A total of 53 NDMM patients were enrolled in the study; the median age at diagnosis was 72 years. The majority (n = 49) of patients experienced treatment-related toxicities; most common toxicities included fatigue (63%) and peripheral neuropathy (PN) of any grade (43%). Fatigue and PN were mostly of grade 1/2 severity. Grade 3/4 toxicities included hypophosphatemia (31%), rash (10%), and PN (2%).

Among the 40 patients who were evaluable for efficacy after 4 cycles, the investigator-reported overall response rate was 90%, including 10 (25%) complete responses, 14 (35%) very good partial responses, and 12 (30%) partial responses. Three patients discontinued treatment after <1 cycle, 1 due to worsening adrenal insufficiency, 1 due to lenalidomide treatment-related rash, and 1 at the investigator’s discretion. Pharmacokinetic analysis showed that plasma concentrations of bortezomib were similar between intravenous and subcutaneous dosing. At median follow-up of 17.2 months in 48 evaluable patients, the 1-year progression-free survival (PFS) was 95% and 2-year PFS was 68%; median overall survival has not been reached. Based on these results, the authors concluded that modified RVD (RVD-lite) was a well-tolerated and highly effective regimen in older transplant-ineligible patients with NDMM.

  1. Benboubker L, et al. N Engl J Med. 2015;371(10):906-917.
  2. O’Donnell EK, et al. ASH 2015. Abstract 4217.
Related Items
Sexual Dysfunction After Cancer: Why Aren’t We Talking About It?
Meg Barbor, MPH
TON - July 2018, Vol 11, No 3 published on July 25, 2018 in ONS 2018, Conference Correspondent
The Importance of Compassion: Perspective From a Lifelong Patient
Meg Barbor, MPH
TON - July 2018, Vol 11, No 3 published on July 25, 2018 in ONS 2018, Conference Correspondent
Using a Team Approach to Tackle Opioid Abuse in Patients with Cancer
Meg Barbor, MPH
TON - July 2018, Vol 11, No 3 published on July 25, 2018 in ONS 2018, Conference Correspondent
Addressing the Second Victim Phenomenon
Charles Bankhead
TON - July 2018, Vol 11, No 3 published on July 25, 2018 in ONS 2018, Conference Correspondent
Palliative Care Use Dismal Among Patients with Hematologic Malignancies
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Conference Correspondent, ASH, Palliative Care, Hematologic Cancers
Oral Multiple Myeloma Medication Linked to Decreased Productivity Loss
Chase Doyle
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Conference Correspondent, ASH, Multiple Myeloma
Ivosidenib, New IDH1 Inhibitor, Elicits Complete Response in Relapsed Acute Myeloid Leukemia
Wayne Kuznar
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Conference Correspondent, Drug Updates, ASH
“Superhero” Navigators Convene at the 8th Annual Navigation & Survivorship Conference
Meg Barbor, MPH
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in AONN+ News, Conference Correspondent
Silent Patients Find Their Voices Through an Advocate’s Journey
Meg Barbor, MPH
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Patient Advocacy, Conference Correspondent, ESMO
Measuring Financial Well-Being in Cancer Survivorship
Meg Barbor, MPH
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Conference Correspondent, Survivorship
Last modified: December 5, 2017